Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort

Oncoinvent CEO, Jan A. Alfheim presented the company at the virtual Hadean Ventures Annual Event 2020. The presentation is available here (https://www.youtube.com/watch?v=f_cJUHC4vSg&feature=emb_logo).    

Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.

Oncoinvent will present the e-poster “Size-controlled 224Ra-labelled calcium carbonate microparticles against peritoneal carcinomatosis” at the virtual 33rd annual European Association of Nuclear Medicine (EANM) Congress. The abstract (no. EP-290) can be downloaded here.

Oncoinvent CEO, Jan A. Alfheim will present the company at the virtual Nordic American Life Science Conference.

Oncoinvent would like to extend an invitation to a presentation of the Q3 2020 results. The presentation will be held virtually at 10:00 on Friday 23. October 2020. We request that participants register with kvam@oncoinvent.com for logon details. The quarterly report will be made available on www.oncoinvent.com on the 23. October 2020.

Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.

Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis

Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.

Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.

Press Release 02.2020:
Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis



Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin®.

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.